Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ottignies – page 30

1 888 clinical trials in Ottignies, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ottignies at a glance
1 888
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 888 trials in Ottignies

Open in trial search

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Fungal infection+3

Recruiting

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Basilea Pharmaceutica International AG Allschwil

Study of cefadroxil effectiveness in adult patients with Staphylococcus aureus bloodstream infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cefadroxil
  • Sponsor:UZ Brussel

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Study Comparing Single and Dual Antiplatelet Therapy with Clopidogrel and Acetylsalicylic Acid in Elderly Patients or Those at Risk of Bleeding After Balloon Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fondazione Ricerca e Innovazione Cardiovascolare

Evaluating NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder Who Are Not Responding Adequately to Current Therapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osavampator
  • Sponsor:Neurocrine Biosciences Inc.

Study of Telisotuzumab Adizutecan for Adults with Colorectal Cancer Who Have Positive Circulating Tumor DNA After Treatment but No Visible Cancer on Scans

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Telisotuzumab adizutecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study of Etranacogene Dezaparvovec (CSL222) in Adolescent Males with Severe or Moderately Severe Hemophilia B

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Etranacogene Dezaparvovec
  • Sponsor:CSL Behring LLC

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ottignies

What the registry says about research in the country

01 Neurology and Consciousness Disorders

Clinical research in Ottignies includes studies focused on nervous system diseases and the recovery of patients with disorders of consciousness after severe brain injury or coma. These trials are exploring whether targeted therapies can improve wakefulness, responsiveness, and overall neurological recovery.

  • Evaluation of ketamine for post-comatose patients with impaired consciousness
  • Assessment of apomorphine hydrochloride for severe brain injury and consciousness recovery
  • Study of zolpidem responses in patients with disorders of consciousness
  • Research into the mechanisms behind paradoxical neurological responses

Together, these trials aim to improve treatment options and deepen understanding of how the brain may respond to therapy in complex neurological conditions.

02 Respiratory Infections and Critical Care

Another active area of research covers respiratory tract diseases, especially severe community-acquired pneumonia and broader respiratory tract infection care in hospitalized patients. The goal is to identify better ways to support recovery and reduce serious outcomes in people admitted with acute infections.

  • Testing supportive interventions for hospitalized patients with acute respiratory tract infection
  • Evaluating treatment options for severe community-acquired pneumonia
  • Measuring effects on survival and recovery over time

This line of research is particularly relevant for intensive care settings, where timely and effective treatment can strongly influence patient outcomes.

03 Oncology and Breast Cancer

In the field of neoplasms, trials are studying advanced breast cancer with specific genetic features, including ER-positive and HER2-negative disease. Research is centered on whether new treatment combinations can improve disease control in patients with hard-to-treat cancers.

  • Testing a combination approach for selected metastatic breast cancer patients
  • Focusing on tumors with BRCA and HRR alterations
  • Assessing benefits in patients with advanced hormone-receptor-positive disease

These studies are designed to evaluate treatment effectiveness and offer more personalized options for people with genetically defined cancer subtypes.

04 Epilepsy and Rare Neurological Syndromes

Research in nervous system diseases also includes long-term treatment studies for rare epileptic disorders such as Dravet syndrome and Lennox-Gastaut syndrome. The emphasis is on improving seizure control while keeping therapy safe and tolerable over time.

  • Long-term safety evaluation of soticlestat as add-on therapy
  • Support for patients already receiving standard epilepsy care
  • Focus on chronic management of Dravet syndrome and Lennox-Gastaut syndrome

This research is important for families and clinicians seeking better options for rare and severe seizure disorders.

05 Women’s Health and Viral Infections

Within female urogenital diseases and pregnancy-related conditions, clinical trials are examining human papillomavirus infection and strategies to help clear persistent genital HPV. The main purpose is to test whether new approaches can improve infection outcomes and reduce long-term risk.

  • Comparing a candidate intervention with placebo for genital HPV clearance
  • Targeting high-risk oncogenic HPV infections
  • Supporting prevention efforts in women’s health

This area links infection control with cancer prevention, making it a meaningful focus in preventive medicine.

06 Vision Research and Physiological Responses

A smaller but distinctive research stream examines physiological processes in people with acquired partial or total vision impairments and in neurotypical volunteers. These studies aim to better understand unusual responses to treatment and how such responses may inform personalized care.

  • Studying temporary visual improvement in patients with vision impairments
  • Comparing responses in volunteers and patient groups
  • Exploring how unusual drug responses may reveal biological mechanisms

The findings may help clarify why some individuals respond differently to the same treatment and support more tailored clinical decisions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.